Impact of omalizumab therapy on medication requirements for XXXX .

@entity1 @entity56 @entity102 @entity479
BACKGROUND: Omalizumab is indicated for treatment of @entity1 with moderate to severe @entity56 . Previous studies have shown 70% of these @entity1 also have @entity102 ( @entity102 ). The present series examines the impact of omalizumab on medication use for @entity102 in a cohort of asthmatic @entity102 @entity1 who received this therapy. METHODS: The sample included 25 @entity1 with adequate prescription data preinitiation and postinitiation of therapy. Data was available for a full 12 months both preinitiation and postinitiation of therapy in 20 of 25 @entity1 and for 4 to 8 months in the remaining 5 of 25. Average antibiotic use (# of unique prescriptions per month) and systemic @entity479 dose (mg/month) were tabulated for each @entity1 and compared before and after initiation of therapy. RESULTS: Mean antibiotic prescriptions/month decreased by 37%, and this was statistically significant (p = 0.013). Antibiotic use decreased in 15 of 25 (60%), was the same in 7 of 25 (28%), and increased in 3 of 25 (12%) @entity1 . Chronic @entity479 administration was required in 19 of 25 @entity1 , and dosing was highly variable. Mean monthly @entity479 dose decreased substantially in 8 of 19 (42%) @entity1 , with reduction ranging from 40% to 100% from pretreatment levels. A modest decrease of 17% to 30% was observed in 4 of 19 (21%) @entity1 . @entity479 use was essentially unchanged in 4 of 19 (21%), but dramatically increased (71% to 366% above pretreatment dose) in 3 of 19 (15%) @entity1 . CONCLUSION: Omalizumab therapy is associated with a decrease in overall antibiotic use for @entity102 . A subset of @entity1 also experience significant reduction in @entity479 dependence. Further study is necessary to determine factors predictive of response.
